Fosfomycin trometamol in the prophylaxis of post‐kidney transplant urinary tract infection: A controlled, randomized clinical trial

Abstract

The addition of FOS to TMP-SMX was not beneficial for the prevention of UTI after RT in our setting. (ClinicalTrials.gov, NCT01820897).

Efficacy and tolerability of fosfomycin in prevention of recurrent urinary tract infections among kidney transplant recipients

“…This was an important study that compared the efficacy of FOS 3 g every 10 days (in addition to TMP-SMX) administered during the first 6 months to KTR (n = 32) vs standard TMP-SMX prophylaxis (n = 35) and found no difference in the incidence of UTI (41 vs 43%) or the median time to UTI (7 days). 1 Although in their study, that included recipients of both living and deceased donors, FOS was not beneficial for the overall prevention of UTI, there was reduced number of patients with UTI due to Escherichia coli and Enterococcus faecalis in the FOS-treated group. 1 Previous reports have shown efficacy of FOS for patients undergoing urological procedures and in females with recurrent UTI.…”

“…1 Although in their study, that included recipients of both living and deceased donors, FOS was not beneficial for the overall prevention of UTI, there was reduced number of patients with UTI due to Escherichia coli and Enterococcus faecalis in the FOS-treated group. 1 Previous reports have shown efficacy of FOS for patients undergoing urological procedures and in females with recurrent UTI. [2][3][4][5] Clinical cure rates were 67% for lower-UTI and 80% for upper-UTI in a study that included 40 KTR.…”

“…longed the time to recurrence compared to placebo 5. However, except for Arreola-Guerra's study,1 little is known about FOS prophylaxis in KTR. We conducted a retrospective study to evaluate the efficacy and tolerability of FOS in adult KTR with history of recurrent UTI (urinary symptoms and urine culture with bacterial count ≥10 5 colony forming units/mL) secondary to extended spectrum beta-lactamase (ESBL) organisms or carbapenem-resistant Enterobacteriaceae (CRE), and at least one episode of urosepsis (defined as UTI associated with bacteremia and/or requiring admission to the hospital) who received FOS (3 g every 10 days up to 6 months) for secondary prophylaxis.…”

Effect of Fosfomycin on Cyclosporine Nephrotoxicity

“…The tromethamine is a proton acceptor used to stabilize the oral formulation of fosfomycin [ 8 ]. We recently conducted a randomized controlled trial at our hospital that showed the efficacy of fosfomycin for prophylaxis of urinary tract infections after kidney transplantations [ 9 ].…”

Fosfomycin for the Treatment of Cystitis in the Abdominal Solid Organ Transplant Population

“…3,5 However, clinical data supporting the use of FOS in aSOT are limited. 3,[6][7][8] The aim of this study was to evaluate the use of FOS for the treatment of cystitis retrospectively in the aSOT population at both the FDA-approved single-dose regimen and the off-label multidose regimens.…”